Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Table 3 Advances of HER2-TKIs

Drug	Brand name	Manufacturer	Targets	Applications of diseases	Approved years or current phases of clinical trials
Lapatinib	Tykerb	GlaxoSmithKline	EGFR, HER2	Combined with capecitabine for HER2-overexpressed metastatic breast cancer who has received prior therapy including an anthracycline, a taxane, and trastuzumab	2007 [76]
Lapatinib	Tykerb	GlaxoSmithKline	EGFR, HER2	Combined with letrozole for 1L postmenopausal HER2-overexpressed and HR + metastatic breast cancer	2010 [78]
Neratinib	Nerlynx	Puma Biotechnology Inc	EGFR, HER2, HER4	Extended adjuvant treatment for patients with early-stage HER2 + breast cancer	2017 [79]
Neratinib	Nerlynx	Puma Biotechnology Inc	EGFR, HER2, HER4	Combined with capecitabine for HER2 + metastatic breast cancer who has received two or more prior anti-HER2 based regimens in the metastatic setting	2020 [80]
Pyrotinib	-	Jiangsu Hengrui	EGFR, HER2, HER4	Combination with capecitabine for HER2-positive metastatic breast cancer	2018^& [81, 82]
Pyrotinib	-	Jiangsu Hengrui	EGFR, HER2, HER4	HER2 exon 20 mutant advanced NSCLC	NCT02535507 [202]
Tucatinib	Tukysa	Seattle Genetics	HER2	Combination with trastuzumab and capecitabine for unresectable or metastatic HER2-Positive breast cancer	2020 [84]

In the last column of “Approved years or current phases of clinical trials”, we provided data of the approved years by Food and Drug Administration (FDA), except pyrotinib with a superscript “&” which means it was approved by National Medical Products Administration (NMPA)
Data source: www.fda.gov, www.drugs.com, and www.clinicaltrials.gov (cutoff date: 19 July 2020)

ISSN: 1756-8722